Table 4.

Treatment-Emergent Adverse Events Regardless of Causality^a

Adverse Event	Ridaforolimus (N = 38) Number of Patients, n (%)
	Total	Grade 3	Grade 4
Hematologic
Anemia	17 (44.7)	0 (0)	0 (0)
Thrombocytopenia	8 (21.1)	2 (5.3)	0 (0)
Neutropenia	6 (15.8)	3 (7.9)	0 (0)
Nonhematologic
Fatigue	31 (81.6)	2 (5.3)	0 (0)
Mucosal inflammation	22 (57.9)	1 (2.6)	0 (0)
Rash	17 (44.7)	0 (0)	0 (0)
Peripheral edema	17 (44.7)	0 (0)	0 (0)
Nausea	17 (44.7)	0 (0)	0 (0)
Diarrhea	16 (42.1)	1 (2.6)	0 (0)
Constipation	14 (36.8)	1 (2.6)	0 (0)
Vomiting	11 (28.9)	1 (2.6)	0 (0)
Anorexia	11 (28.9)	0 (0)	0 (0)
Arthralgia	11 (28.9)	0 (0)	0 (0)
Dyspnea	10 (26.3)	1 (2.6)	0 (0)
Cough	10 (26.3)	0 (0)	0 (0)
Back pain	10 (26.3)	0 (0)	0 (0)
Pyrexia	9 (23.7)	0 (0)	0 (0)
Hypertriglyceridemia	8 (21.1)	0 (0)	1 (2.6)
Pain in extremity	8 (21.1)	1 (2.6)	0 (0)
Nail disorder	8 (21.1)	0 (0)	0 (0)
Hyperglycemia	7 (18.4)	2 (5.3)	1 (2.6)
Stomatitis	7 (18.4)	0 (0)	0 (0)
Decreased appetite	7 (18.4)	0 (0)	0 (0)
Upper respiratory tract infection	7 (18.4)	0 (0)	0 (0)
Epistaxis	6 (15.8)	0 (0)	0 (0)
Hypokalemia	4 (10.5)	2 (5.3)	0 (0)
Pruritis	4 (10.5)	1 (2.6)	0 (0)

^aAdverse events occurring in 15% of patients or more, and all grade 3 or 4 adverse events.